Moody Aldrich Partners’s Dianthus Therapeutics DNTH Stock Holding History

Moody Aldrich Partners’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.27M	Sell	74,552 -7,577	-9%	-$662K	1.31%	12
2026 Q1	$6.89M	Buy	82,129 +40,825	+99%	+$2.36M	1.24%	11
2025 Q4	$1.7M	Sell	41,304 -1,987	-5%	-$77K	0.32%	113
2025 Q3	$1.7M	Sell	43,291 -29,975	-41%	-$766K	0.32%	105
2025 Q2	$1.36M	Sell	73,266 -1,106	-1%	-$20.7K	0.26%	105
2025 Q1	$1.35M	Buy	+74,372	New	+$1.64M	0.28%	106

Other funds holding DNTH

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PFA

Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

GBT

Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Moody Aldrich Partners's DNTH Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Dianthus Therapeutics (DNTH) stake by 9.2% in Q2 2026, selling an estimated $662K and leaving 74,552 shares worth $7.27M. The position accounts for 1.31% of the portfolio, ranked #12.

Moody Aldrich Partners first reported a position in DNTH in Q1 2025 and has held it in 6 quarters since. 12 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Moody Aldrich Partners held 74,552 shares of Dianthus Therapeutics worth $7.27M as of Q2 2026.
Moody Aldrich Partners sold 7,577 Dianthus Therapeutics shares in Q2 2026, an estimated $662K.
Dianthus Therapeutics made up 1.31% of Moody Aldrich Partners's portfolio in Q2 2026, its #12 holding.
Moody Aldrich Partners first reported a position in Dianthus Therapeutics in Q1 2025 and has held it in 6 quarters since.
12 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.